Company news

Immunome, Inc. news in 2021

Immunome, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald

December 6, 2021

Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant

November 30, 2021

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

November 28, 2021

Immunome Reports Third Quarter 2021 Financial Results

November 14, 2021

Immunome to Present at the Stifel Healthcare Conference

November 8, 2021

Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

October 19, 2021

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 6, 2021

Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 29, 2021

Immunome to Present at the Cantor Global Healthcare Conference

September 21, 2021

Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

September 14, 2021

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

September 6, 2021

Immunome Reports Second Quarter 2021 Financial Results

August 18, 2021

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

July 19, 2021

Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

July 5, 2021

Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

June 29, 2021

Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors

June 16, 2021

Immunome to Present at the Jefferies Virtual Healthcare Conference

May 26, 2021

Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

May 19, 2021

Immunome Reports First Quarter 2021 Financial Results

May 11, 2021

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

April 25, 2021

Immunome Announces $27 Million Private Placement

April 25, 2021

Immunome Appoints Corleen Roche as Chief Financial Officer

April 19, 2021

Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

March 29, 2021

Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

March 24, 2021

Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies

March 22, 2021

Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

February 17, 2021

Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus

January 31, 2021

Decks in 2021